Natco Pharma reports start of a facility in Vizag

The share of Natco Pharma traded higher after the company reported that it has begun commercial operations at its Finished constructed Dosage Formulations (FDF) facility in Visakhapatnam.

The company, in its stock exchange filing, said that the facility is part of Special Economic Zone (SEZ) and is intended to cater primarily to the US and other international markets. It has commenced commercial operations at the Visakhapatnam-based FDF facility.

The company further added that the Vizag facility is a key part of its capacity expansion plans for its product pipeline and the diversification into various geographies. From a capability perspective, this facility will focus mostly on oral solid dosages (tablets and capsules), including a cytotoxic block for products in the oncology segment. An application has already been filed with the US Food and Drug Administration (USFDA) for the site transfer of the first product and to trigger a regulatory audit.

Natco Pharma is engaged in research and development (R&D) and marketing of pharmaceutical products, together with finished dosage, for the domestic and international markets.

The stock price on Friday touched its intra-day high Rs. 567.05. At 11.00 am, the stock traded with gains of 1.22 per cent, that is, at Rs. 566.25 on BSE.